CN100488503C - 一种治疗心脑血管疾病的药物组合物 - Google Patents
一种治疗心脑血管疾病的药物组合物 Download PDFInfo
- Publication number
- CN100488503C CN100488503C CNB2005101293918A CN200510129391A CN100488503C CN 100488503 C CN100488503 C CN 100488503C CN B2005101293918 A CNB2005101293918 A CN B2005101293918A CN 200510129391 A CN200510129391 A CN 200510129391A CN 100488503 C CN100488503 C CN 100488503C
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- bilobalide
- cerebrovascular disease
- acid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 9
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 claims abstract description 44
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 17
- 150000004291 polyenes Chemical class 0.000 claims abstract description 13
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 5
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004380 Cholic acid Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- -1 bilobalide sodium salt Chemical class 0.000 claims description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 3
- 235000019416 cholic acid Nutrition 0.000 claims description 3
- 229960002471 cholic acid Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 claims description 3
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 claims description 2
- 229960002997 dehydrocholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000008347 soybean phospholipid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000218628 Ginkgo Species 0.000 description 4
- 235000011201 Ginkgo Nutrition 0.000 description 4
- 235000008100 Ginkgo biloba Nutrition 0.000 description 4
- 238000005352 clarification Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗心脑血管疾病的药物组合物，主要由银杏内酯与多烯磷脂酰胆碱组成。它能改善心脑血管疾病患者疾病组织的血流量，增加疾病组织中的磷脂含量，保护疾病组织细胞膜的完整，具有显著的治疗作用。
Description
本发明涉及的是一种具有治疗心脑血管疾病作用的药物。
银杏内酯是由银杏叶中提取的一类重要有效成分，主要含有银杏内酯A、B及少量的银杏内酯C，其他还含有微量的银杏内酯J、M及白果内酯等。药理研究表明银杏内酯是高效的天然抗血小板激活因子(PAF)受体拮抗剂，可抑制血小板聚集，降低血液黏度，改善缺血病人的微循环，减少血栓形成，非常有潜力成为临床上治疗心脑血管疾病的药物。目前国内已有众多厂家正在将银杏内酯开发为注射剂型的药物。
大豆磷脂(英文名称Soya Lecithin)是从大豆中提取的一种药用物质，又名大豆卵磷脂，为制药工业常用的药用原料。大豆磷脂内含丰富的磷脂酰胆碱(英文名称Phosphatidyl choline)，并含有丰富的结合型不饱和脂肪酸，主要为亚油酸、亚麻酸和油酸等。目前我国已有国家标准的大豆磷脂原料及其相关制剂生产和销售。
多烯磷脂酰胆碱是对大豆磷脂进行进一步纯化加工制得的高纯度大豆磷脂，内含丰富的结合型不饱和脂肪酸，主要为亚油酸、亚麻酸和油酸等，我国目前已批准了该品原料的生产及销售。多烯磷脂酰胆碱在化学结构上与重要的内源性磷脂一致，而且在功能上优于后者，其制剂临床上主要用于治疗各种类型的肝病。如：肝炎、肝硬化、肝坏死、肝昏迷、脂肪肝和胆汁阻塞等，目前我国已有多烯磷脂酰胆碱胶囊及其注射液进口。
综合而言，目前临床上治疗脑中风、心肌梗塞等心脑血管疾病的药物虽然众多，但是西药或单一的化学药品作用机理单一，临床上综合治疗效果基本上不尽人意；中药注射剂具有多机理协同治疗的作用，近年来临床用量增长迅速，由于目前常见的中药注射剂成分复杂不清，不良反应发生率较高，口服中药制剂起效慢，该类药也满足不了临床患者的要求。目前临床上急需成分明确、安全有效的心脑血管疾病治疗药。
本发明的目的就是提供一种治疗心脑血管病的药物组合物，该药物组合物能产生综合协同作用，显著优于单用同剂量银杏内酯的效果。
本发明所要解决的技术问题是通过以下的技术方案来实现的，它由银杏内酯和多烯磷脂酰胆碱两种原料组成，其中银杏内酯可用相当比例量的银杏叶提取物或其可药用性盐替换(以内含的银杏内酯总量折算)，多烯磷脂酰胆碱可用相当比例量的大豆磷脂替换(以标示的磷脂酰胆碱纯品计算)。银杏内酯与多烯磷脂酰胆碱的重量比一般为1：1-30，较好的是1：10。药物处方中加入一定量的胆酸或其可药用性盐、去氢胆酸或其可药用性盐、脱氧胆酸或其可药用性盐、甘氨胆酸或其可药用性盐作为辅料，以改善主药银杏内酯和多烯磷脂酰胆碱的溶解性能。
本发明的药物组合物的疗效由以下药效学试验证明：
1、犬大脑中动脉结扎脑缺血模型试验
材料：动物：中国草种犬，体重8—12kg；药品：银杏内酯注射液(20mg/支)及复方银杏内酯多烯磷脂酰胆碱注射液(20+200mg/支)，自制。
表一 受试药品对实验性犬脑缺血的影响
| 组别 | 对照组 | 试验组 |
| 受试药品 | 银杏内酯注射液 | 复方银杏内酯多烯磷脂酰胆碱注射液 |
| 脑重量 | 65.58±2.4 | 62.36±5.7 |
| 脑组织缺血区重量 | 13.98±2.8 | 10.58±3.6 |
| 缺血区脑重比(％) | 21.31 | 16.96 |
| 脑磷脂下降率(％) | 34％ | 10％ |
表一结果显示，和对照组药物比较，试验组药物能显著降低缺血区脑重比，显著减少脑磷脂的下降，对大脑功能具有更好保护作用。
2、犬冠状动脉前降支结扎所致心肌梗塞模型试验
表二 受试药品对心肌梗塞犬模型试验的影响
由表二可见，和对照组比较，试验组药品能显著降低模型动物的LDH和CPK，明显缩小左心室梗塞范围，对心脏具有更好的保护作用。
下面用实施例对本发明进行说明，但本发明并不局限于这些实施例。
实施例1：软胶囊剂
工艺示例：取活性成分，植物油适量、加入辅料，混匀，压制成软胶囊，即制得含有1份银杏内酯和10份多烯磷脂酰胆碱的软胶囊剂型的药物组合物。
实施例2：胶囊剂
工艺示例：取活性成分、胆酸、微粉硅胶、羧甲基淀粉钠混匀，上胶囊填充机，压制得到胶囊剂。
实施例3：小容量注射液
工艺示例：取胆酸钠，加入适量水溶解制成胆酸钠溶液；取处方量的主药，用适量乙醇溶解至澄清，搅拌加入上述胆酸钠溶液中，搅拌溶液至澄清，补加注射用水，调节溶液pH到8，加入0.3％活性炭，常温搅拌15分钟，过滤、充氮分装，封瓶、灭菌，即得。
实施例4：冻干粉针
工艺示例：取去氢胆酸钠，加入适量水溶解制成去氢胆酸钠溶液；取处方量主药，用适量乙醇溶解至澄清，搅拌加入上述去氢胆酸钠溶液中，搅拌溶液至澄清，加入甘露醇，补加注射用水，调节溶液pH到8，加入0.3％活性炭，常温搅拌15分钟，过滤、冷冻干燥，即得。
银杏内酯可直接购买市售产品，亦可购买含有银杏内酯的市售银杏叶提取物，产品质量应符合中国药典银杏叶提取物质量标准要求，投料时以内含的总银杏内酯折算替换。多烯磷脂酰胆碱可直接购买市售产品，产品质量应符合国家药品标准。大豆磷脂可购买上海太伟药业有限公司、德国Degussa公司或德国Lipoid公司或其他公司的市售产品，产品质量应符合国家药品标准，投料时以内含的磷脂酰胆碱折算替换。
Claims (5)
1、一种治疗心脑血管疾病的药物组合物，其特征在于，所述药物组合物基本上由1重量份银杏内酯与10重量份多烯磷脂酰胆碱组成。
2、根据权利要求1所述的药物组合物，其特征在于，所述银杏内酯用银杏内酯钠盐、银杏内酯钾盐或银杏内酯葡甲胺盐替换。
3、根据权利要求1所述的药物组合物，其特征在于，所述药物组合物的剂型为注射液或冻干粉针剂。
4、根据权利要求1所述的药物组合物，其特征在于，所述药物组合物的剂型为胶囊剂。
5、根据权利要求1所述的药物组合物，其特征在于，还含有以下药物辅料中的至少一种辅料：胆酸或胆酸钠、去氢胆酸或去氢胆酸钠、脱氧胆酸。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101293918A CN100488503C (zh) | 2005-04-06 | 2005-12-07 | 一种治疗心脑血管疾病的药物组合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510020668.3 | 2005-04-06 | ||
| CNA2005100206683A CN1726923A (zh) | 2005-04-06 | 2005-04-06 | 一种治疗心脑血管疾病的药物组合物 |
| CNB2005101293918A CN100488503C (zh) | 2005-04-06 | 2005-12-07 | 一种治疗心脑血管疾病的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1843350A CN1843350A (zh) | 2006-10-11 |
| CN100488503C true CN100488503C (zh) | 2009-05-20 |
Family
ID=37062336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101293918A Expired - Fee Related CN100488503C (zh) | 2005-04-06 | 2005-12-07 | 一种治疗心脑血管疾病的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100488503C (zh) |
-
2005
- 2005-12-07 CN CNB2005101293918A patent/CN100488503C/zh not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 天然活性成分磷脂复合物药学研究概述. 吴建梅等.中国药学杂志，第33卷第1期. 1998 |
| 天然活性成分磷脂复合物药学研究概述. 吴建梅等.中国药学杂志，第33卷第1期. 1998 * |
| 银杏叶提取物磷脂酰胆碱复合物的药效学研究. 刘进进等.医学新知杂志，第13卷第1期. 2003 |
| 银杏叶提取物磷脂酰胆碱复合物的药效学研究. 刘进进等.医学新知杂志，第13卷第1期. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1843350A (zh) | 2006-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7763284B2 (en) | Method for treating or preventing symptoms associated with menopause | |
| EP2730286B1 (en) | Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints | |
| US20120122824A1 (en) | Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer | |
| CN1391464A (zh) | 绝经妇女用制剂 | |
| JPH0832230B2 (ja) | 食品組成物 | |
| CN1092973C (zh) | 乳香或乳香亲脂性提取物在制备用于治疗阿尔茨海默症的药物中的用途 | |
| CN101244016A (zh) | 柚皮苷在制备口腔护理保健品中的应用 | |
| US10894070B2 (en) | Drug compound for the control of blood glucose, blood lipids and weight | |
| WO2006111085A1 (fr) | Procede, formulation et utilisation de medicaments ou de nutriments avec une absorption orale amelioree | |
| CN102068494B (zh) | 对化学性肝损伤有治疗作用的保健胶囊及其制备方法 | |
| CN102698031A (zh) | 右归胶囊及其制备方法 | |
| EP3515428B1 (en) | Method to alleviate the symptoms of pms | |
| JP5523663B2 (ja) | 歯根−歯周組織形成促進用医薬組成物 | |
| CN100488503C (zh) | 一种治疗心脑血管疾病的药物组合物 | |
| KR100419121B1 (ko) | 여성 갱년기 증상의 개선 기능을 갖는 생약조성물을함유하는 기능성 식품 | |
| CN1230191C (zh) | 一种蜂胶降糖降脂保健组合物及其胶囊的制造方法 | |
| CN102626420B (zh) | 一种含有锶、钙和维生素d的混合制剂 | |
| CN106511394B (zh) | 九香虫脂肪油提取物的用途 | |
| CN1726923A (zh) | 一种治疗心脑血管疾病的药物组合物 | |
| CN112353837B (zh) | 葛花提取物及其用途 | |
| JP4578760B2 (ja) | 更年期障害治療用組成物、性ホルモン上昇用組成物 | |
| WO2018222164A9 (en) | USE OF HERB-BASED PREPARATION CONTAINING POUPINE OIL CONTAINING POULTRY OIL IN THE TREATMENT OF BPH | |
| TW201834680A (zh) | 性早熟症的預防或改善用食品組合物及性早熟症的預防或治療用藥學組合物 | |
| US3894153A (en) | Method of medical treatment of asthma | |
| JP2006131572A (ja) | 月経関連症状の緩和剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XIZHANG KANGXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENGDU BORUI PHARMACEUTICAL SCIENCE AND TECHNOLOGY DEVELOPMENT Effective date: 20090515 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090515 Address after: Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Tibet Kangxin Pharmaceutical Co., Ltd. Address before: B-C-36, building, high tech incubator Park, South extension Road, Tianfu Road, Sichuan, China Patentee before: Chengdu Boling Pharmaceutical Co., Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Sichuan Haisco Pharmaceutical Co.,Ltd. Assignor: Tibet Kangxin Pharmaceutical Co., Ltd. Contract fulfillment period: 2009.6.18 to 2014.6.18 Contract record no.: 2009510000035 Denomination of invention: Composition of medication for treating cardiovascular diseases and cerebrovascular diseases Granted publication date: 20090520 License type: Exclusive license Record date: 2009.9.16 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.6.18 TO 2014.6.18; CHANGE OF CONTRACT Name of requester: SICHUAN HAISIKE PHARMACEUTICAL CO., LTD. Effective date: 20090916 |
|
| C56 | Change in the name or address of the patentee |
Owner name: XIZANG HAISIKE PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: XIZANG KANGXIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Tibetan Haisike Pharmaceutical Group Co., Ltd. Address before: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee before: Tibet Kangxin Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Tibet Haisco Pharmaceutical Group Co., Ltd. Address before: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee before: Tibetan Haisike Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Haisike Pharmaceutical Group Limited by Share Ltd Address before: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee before: Tibet Haisco Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090520 Termination date: 20181207 |